Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company has collaboration agreement with Novartis to conduct three Phase IIb clinical trials Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-376-2600
Debt
Current Ratio2.39
Quick Ratio2.39
Price-To-Earnings
Sales & Book Value
Annual Sales$35.38 million
Price / Sales1.60
Price / Cash FlowN/A
Price / Book2.01
Profitability
Net Income$-17,390,000.00
Net Margins-52.77%
Return on Assets-26.03%
Miscellaneous
Employees35
OptionableOptionable
Conatus Pharmaceuticals (NASDAQ:CNAT) Frequently Asked Questions
What is Conatus Pharmaceuticals' stock symbol?
Conatus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNAT."
How were Conatus Pharmaceuticals' earnings last quarter?
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) issued its quarterly earnings results on Thursday, November, 1st. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.15). The biotechnology company had revenue of $7.67 million for the quarter, compared to analysts' expectations of $9.70 million. Conatus Pharmaceuticals had a negative return on equity of 83.99% and a negative net margin of 52.77%. View Conatus Pharmaceuticals' Earnings History.
When is Conatus Pharmaceuticals' next earnings date?
What price target have analysts set for CNAT?
5 analysts have issued twelve-month price objectives for Conatus Pharmaceuticals' stock. Their predictions range from $4.00 to $20.00. On average, they expect Conatus Pharmaceuticals' stock price to reach $11.1150 in the next twelve months. This suggests a possible upside of 494.4% from the stock's current price. View Analyst Price Targets for Conatus Pharmaceuticals.
What is the consensus analysts' recommendation for Conatus Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Conatus Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Conatus Pharmaceuticals.
Has Conatus Pharmaceuticals been receiving favorable news coverage?
News stories about CNAT stock have been trending somewhat positive recently, according to InfoTrie. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Conatus Pharmaceuticals earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 7.0 out of 10, meaning that recent news coverage is likely to have an effect on the company's share price in the immediate future.
Are investors shorting Conatus Pharmaceuticals?
Conatus Pharmaceuticals saw a drop in short interest in December. As of December 14th, there was short interest totalling 2,338,397 shares, a drop of 27.1% from the November 30th total of 3,207,010 shares. Based on an average daily volume of 2,077,405 shares, the days-to-cover ratio is presently 1.1 days. Approximately 8.9% of the company's shares are short sold. View Conatus Pharmaceuticals' Current Options Chain.
Who are some of Conatus Pharmaceuticals' key competitors?
Some companies that are related to Conatus Pharmaceuticals include MannKind (MNKD), Affimed (AFMD), CELYAD SA/ADR (CYAD), Kamada (KMDA), Syros Pharmaceuticals (SYRS), Kala Pharmaceuticals (KALA), TAIWAN LIPOSOME/S (TLC), Aeglea Bio Therapeutics (AGLE), Arbutus Biopharma (ABUS), Athersys (ATHX), XBiotech (XBIT), Paratek Pharmaceuticals (PRTK), Aratana Therapeutics (PETX), LifeVantage (LFVN) and MEI Pharma (MEIP).
Who are Conatus Pharmaceuticals' key executives?
Conatus Pharmaceuticals' management team includes the folowing people:
- Dr. Steven J. Mento, Co-Founder, Pres, CEO & Director (Age 66)
- Dr. Keith W. Marshall MBA, Ph.D., Exec. VP, COO & CFO (Age 50)
- Dr. David T. Hagerty, Exec. VP of Clinical Devel. (Age 63)
- Dr. Alfred P. Spada, Co-Founder, Exec. VP of R&D and Chief Scientific Officer (Age 60)
- Mr. Alan R. Engbring, Exec. Director of Investor Relations & Corp. Communications
How do I buy shares of Conatus Pharmaceuticals?
Shares of CNAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Conatus Pharmaceuticals' stock price today?
One share of CNAT stock can currently be purchased for approximately $1.87.
How big of a company is Conatus Pharmaceuticals?
Conatus Pharmaceuticals has a market capitalization of $55.08 million and generates $35.38 million in revenue each year. The biotechnology company earns $-17,390,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. Conatus Pharmaceuticals employs 35 workers across the globe.
What is Conatus Pharmaceuticals' official website?
How can I contact Conatus Pharmaceuticals?
Conatus Pharmaceuticals' mailing address is 16745 WEST BERNARDO DRIVE Suite 200, San Diego CA, 92127. The biotechnology company can be reached via phone at 858-376-2600 or via email at [email protected]
MarketBeat Community Rating for Conatus Pharmaceuticals (NASDAQ CNAT)
MarketBeat's community ratings are surveys of what our community members think about Conatus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CNAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNAT will underperform the S&P 500 over the long term. You may vote once every thirty days.
